165 related articles for article (PubMed ID: 18928444)
1. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.
Drini M; Prichard PJ; Brown GJ; Macrae FA
Med J Aust; 2008 Oct; 189(8):464-5. PubMed ID: 18928444
[TBL] [Abstract][Full Text] [Related]
2. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy.
Zeidan A; Sham R; Shapiro J; Baratta A; Kouides P
Leuk Lymphoma; 2007 Jul; 48(7):1410-3. PubMed ID: 17613771
[No Abstract] [Full Text] [Related]
3. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.
Ochenrider MG; Patterson DJ; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):144-8. PubMed ID: 20371449
[TBL] [Abstract][Full Text] [Related]
4. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?
Rosh JR; Gross T; Mamula P; Griffiths A; Hyams J
Inflamm Bowel Dis; 2007 Aug; 13(8):1024-30. PubMed ID: 17480018
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
Kotlyar DS; Osterman MT; Diamond RH; Porter D; Blonski WC; Wasik M; Sampat S; Mendizabal M; Lin MV; Lichtenstein GR
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
[TBL] [Abstract][Full Text] [Related]
6. Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.
Selvaraj SA; Chairez E; Wilson LM; Lazarev M; Bass EB; Hutfless S
Syst Rev; 2013 Jul; 2():53. PubMed ID: 23826928
[TBL] [Abstract][Full Text] [Related]
7. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease.
Thayu M; Markowitz JE; Mamula P; Russo PA; Muinos WI; Baldassano RN
J Pediatr Gastroenterol Nutr; 2005 Feb; 40(2):220-2. PubMed ID: 15699701
[No Abstract] [Full Text] [Related]
8. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.
Mackey AC; Green L; Leptak C; Avigan M
J Pediatr Gastroenterol Nutr; 2009 Mar; 48(3):386-8. PubMed ID: 19274799
[No Abstract] [Full Text] [Related]
9. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
Mackey AC; Green L; Liang LC; Dinndorf P; Avigan M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):265-7. PubMed ID: 17255842
[TBL] [Abstract][Full Text] [Related]
10. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy.
van de Meeberg MM; Derikx LA; Sinnige HA; Nooijen P; Schipper DL; Nissen LH
World J Gastroenterol; 2016 Dec; 22(47):10465-10470. PubMed ID: 28058028
[TBL] [Abstract][Full Text] [Related]
11. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
Parakkal D; Sifuentes H; Semer R; Ehrenpreis ED
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
[TBL] [Abstract][Full Text] [Related]
12. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.
Rosh JR; Oliva-Hemker M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):165-7. PubMed ID: 17255825
[No Abstract] [Full Text] [Related]
13. Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree?
Moran G; Dillon J; Green J
Inflamm Bowel Dis; 2009 Sep; 15(9):1281-2. PubMed ID: 19067412
[No Abstract] [Full Text] [Related]
14. Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
Thai A; Prindiville T
J Crohns Colitis; 2010 Nov; 4(5):511-22. PubMed ID: 21122554
[TBL] [Abstract][Full Text] [Related]
15. Pancytopenia in a Young Male Patient With Inflammatory Bowel Disease.
Jansson-Knodell CL; Walker MJ; Fischer M
Gastroenterology; 2021 Apr; 160(5):1483-1485. PubMed ID: 32777287
[No Abstract] [Full Text] [Related]
16. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
17. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
Lakatos PL
Rev Recent Clin Trials; 2009 Sep; 4(3):152-8. PubMed ID: 20028325
[TBL] [Abstract][Full Text] [Related]
18. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.
Burger DC; Florin TH
Med J Aust; 2009 Mar; 190(6):341-2. PubMed ID: 19296822
[No Abstract] [Full Text] [Related]
19. An unusual presentation of T-lymphoma in a Crohn's disease patient treated with combo therapy: we are willing to take a risk of serious adverse events for a doubtful benefit?
Sinagra E; Romano C; Virdone R; Orlando E; Cottone M; Orlando A
J Crohns Colitis; 2012 Oct; 6(9):954-5. PubMed ID: 22771136
[No Abstract] [Full Text] [Related]
20. Hepatosplenic αβ T-cell lymphoma arising after long-term azathioprine therapy successfully treated with allogeneic bone marrow transplant.
Bašić Kinda S; Duraković N; Dotlić S; Serventi Seiwerth R; Davidović Mrsić S; Dubravčić K; Aurer I
Leuk Lymphoma; 2013 Jun; 54(6):1334-5. PubMed ID: 23083012
[No Abstract] [Full Text] [Related]
[Next] [New Search]
